Comparison of Diagnostic Sensitivity Between ctDNA Methylation and CEA in Colorectal Cancer
Study Details
Study Description
Brief Summary
This is a comparative study. This study is to compare the diagnostic sensitivity between circulating tumor DNA methylation and carcinoembryonic antigen in detecting colorectal cancer. There are two steps in this study. Firstly, the diagnostic model is established based on tumor-specific plasma circulating tumor DNA methylation markers. Secondly, the sensitivity, specificity and accuracy of plasma circulating tumor DNA methylation are compared with that of carcinoembryonic antigen in detecting colorectal cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Colorectal cancer (CRC) is the third most common cancer worldwide, the second deadliest cancer. It is reported that patients prefer non-invasive methods rather than invasive methods for the detection of CRC. Carcinoembryonic antigen (CEA) is commonly employed in clinical practice for early detection of CRC, but it is limited for its low sensitivity, which is around 30%-40%. DNA methylation is a commonly used biomarker for non-invasive tumor detection in plasma. We aim to develop and validate a methylation-based blood test for CRC based on genome-wide methylation detection. There are two steps. Firstly, this prospective, clinical study aims to establish the diagnostic model based on tumor-specific plasma ctDNA methylation markers. Secondly, this study is to compare the sensitivity, specificity, accuracy, positive predictive value and negative predictive value of plasma circulating tumor DNA (ctDNA) methylation with CEA in detecting colorectal cancer.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cancer group Patients with colorectal cancer. |
Diagnostic Test: Detection of ctDNA methylation
Detection for colorectal tumor-specific plasma ctDNA methylation markers before treatment
|
| Control group Patients with benign colorectal disease. |
Diagnostic Test: Detection of ctDNA methylation
Detection for colorectal tumor-specific plasma ctDNA methylation markers before treatment
|
Outcome Measures
Primary Outcome Measures
- Diagnostic sensitivity [3 years]
The comparison of diagnostic sensitivity between ctDNA methylation and CEA in detecting colorectal cancer
Secondary Outcome Measures
- Diagnostic specificity, accuracy, positive predictive value and negative predictive value [3 years]
The comparison of diagnostic specificity, accuracy, positive predictive value and negative predictive value between ctDNA methylation and CEA in detecting colorectal cancer
Eligibility Criteria
Criteria
Inclusion Criteria:
Cancer group
-
Patients must have histologically confirmed colorectal cancer before or after drawing blood sample.
-
Patients need to receive surgical resection or endoscopic resection.
-
Patients have a performance status of ≤1 on the ECOG Performance Scale.
-
Written informed consent must be obtained.
Control group
-
Written informed consent must be obtained.
-
Individuals must receive colonoscopy.
Exclusion Criteria:
-
Patients received tumor treatment prior to the drawn of blood sample, including surgical resection,neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy and targeted therapy.
-
Patients received antibiotics regularly.
-
Patients received blood transfusion two weeks before the drawn of blood sample.
-
Patients with indications of emergency surgery, including bleeding, obstruction and perforation.
-
Patients who are positive for Human Immunodeficiency Virus (HIV).
-
Patients with abnormal liver and kidney function.
-
Patients with the history of inflammatory bowel disease.
-
Patients who had history of other malignancies.
-
Patients who are pregnant or breastfeeding.
-
Alcoholic or drug abusers.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Nanfang Hospital, Southern Medical University | Guangzhou | Guangdong | China | 510000 |
Sponsors and Collaborators
- Nanfang Hospital of Southern Medical University
Investigators
- Study Chair: Jun Yan, M.D., Ph.D., Nanfang Hospital of Southern Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
- Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, Dhein J, Zimmermann M, Tauber R, Wiedenmann B. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014 Oct 17;14:183. doi: 10.1186/1471-230X-14-183.
- Cai G, Cai M, Feng Z, Liu R, Liang L, Zhou P; ColonAiQ Group; Zhu B, Mo S, Wang H, Lan X, Cai S, Xu Y, Wang R, Dai W, Han L, Xiang W, Wang B, Guo W, Zhang L, Zhou C, Luo B, Li Y, Nie Y, Ma C, Su Z. A Multilocus Blood-Based Assay Targeting Circulating Tumor DNA Methylation Enables Early Detection and Early Relapse Prediction of Colorectal Cancer. Gastroenterology. 2021 Dec;161(6):2053-2056.e2. doi: 10.1053/j.gastro.2021.08.054. Epub 2021 Sep 4. No abstract available.
- Grotowski M. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer]. Pol Merkur Lekarski. 2002 Jan;12(67):77-80. Polish.
- Kanwal R, Gupta K, Gupta S. Cancer epigenetics: an introduction. Methods Mol Biol. 2015;1238:3-25. doi: 10.1007/978-1-4939-1804-1_1.
- Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T, Wang Y, Qiu F, Wu Y, Su J, Xu J, Xu F, Chu H, Fang S, Yang X, Wu C, Cao Z, Cao L, Bing Z, Liu H, Li L, Huang C, Qin Y, Cui Y, Han-Zhang H, Xiang J, Liu H, Guo X, Li S, Zhao H, Zhang Z. Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021 Jun;5(6):586-599. doi: 10.1038/s41551-021-00746-5. Epub 2021 Jun 15. Erratum In: Nat Biomed Eng. 2021 Nov;5(11):1402.
- Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524):eaax7533. doi: 10.1126/scitranslmed.aax7533. Erratum In: Sci Transl Med. 2020 Apr 22;12(540):
- Schilsky RL, Nass S, Le Beau MM, Benz EJ Jr. Progress in Cancer Research, Prevention, and Care. N Engl J Med. 2020 Sep 3;383(10):897-900. doi: 10.1056/NEJMp2007839. No abstract available.
- Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12. Erratum In: CA Cancer J Clin. 2021 Jul;71(4):359.
- Xie H, Mahoney DW, Foote PH, Burger KN, Doering KA, Taylor WR, Then SS, Cao X, McGlinch M, Berger CK, Wu TT, Hubbard JM, Allawi HT, Kaiser MW, Lidgard GP, Ahlquist DA, Kisiel JB. Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. Clin Cancer Res. 2021 Jan 1;27(1):141-149. doi: 10.1158/1078-0432.CCR-20-2589. Epub 2020 Oct 7.
- Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X, Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017 Nov;16(11):1155-1161. doi: 10.1038/nmat4997. Epub 2017 Oct 9.
- NFEC-2022-245